New York-based central nervous system (CNS) specialist Axsome Therapeutics (Nasdaq: AXSM) has hit a regulatory snag in the development of AXS-05 (dextromethorphan/bupropion).
The novel oral medicine, an NMDA receptor blocker, boasts positive Phase III data from the ACCORD trial for the treatment of Alzheimer’s disease (AD) agitation.
However, hopes that a new drug application for AXS-05 in this indication would be possible using results from ACCORD alone have now been set aside.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze